3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dioscin enhances methotrexate absorption by down-regulating MDR1 in vitro and in vivo.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The purpose of this study was to investigate the enhancing effect of dioscin on the absorption of methotrexate (MTX) and clarify the molecular mechanism involved in vivo and in vitro. Dioscin increased MTX chemosensitivity and transepithelial flux in the absorptive direction, significantly inhibiting multidrug resistance 1 (MDR1) mRNA and protein expression and MDR1 promoter and nuclear factor κ-B (NF-κB) activities in Caco-2 cells. Moreover, inhibitor κB-α (IκB-α) degradation was inhibited by dioscin. Dioscin enhanced the intracellular concentration of MTX by down-regulating MDR1 expression through a mechanism that involves NF-κB signaling pathway inhibition in Caco-2 cells. Dioscin strengthened MTX absorption by inhibiting MDR1 expression in rat intestine. In addition, even though MTX is absorbed into the enterocytes, there was no increase in toxicity observed, and that, in fact, decreased toxicity was seen.

          Related collections

          Author and article information

          Journal
          Toxicol. Appl. Pharmacol.
          Toxicology and applied pharmacology
          Elsevier BV
          1096-0333
          0041-008X
          Jun 01 2014
          : 277
          : 2
          Affiliations
          [1 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: jlwang1979@163.com.
          [2 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: wangcyuan@163.com.
          [3 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: jinyongpeng2005@163.com.
          [4 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: llaqii@yahoo.com.cn.
          [5 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: mengq531@yahoo.cn.
          [6 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: sunhuijun@hotmail.com.
          [7 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: huoxiaokui@163.com.
          [8 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: spfar1004@gmail.com.
          [9 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: bocai789770@163.com.
          [10 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: zhenyhwaner@yahoo.com.cn.
          [11 ] Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, Liaoning, PR China; Provincial Key Laboratory for Pharmacokinetics and Transport, Liaoning, Dalian Medical University, Dalian, Liaoning, PR China. Electronic address: kexinliu@dlmedu.edu.cn.
          Article
          S0041-008X(14)00099-4
          10.1016/j.taap.2014.03.013
          24680847
          de14553b-00ca-485c-a918-3ef0b7bda258
          History

          Inhibitor κB-α,Dioscin,Methotrexate,Nuclear factor κ-B,Absorption

          Comments

          Comment on this article